Ladenburg lowered the firm’s price target on Strata Skin Sciences (SSKN) to $14 from $16 and keeps a Buy rating on the shares. The firm is adjusting its price target to reflect topline estimate changes and reduced number of years discounted, but believes there continue to be significant growth opportunities for both XTRAC and TheraClear, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SSKN:
- Strata Skin Sciences Reports Positive Earnings with Key Growth Areas
- STRATA Skin Sciences Reports Growth Amid Strategic Shifts
- Strata Skin Sciences Reports Q4 2024 Financial Results
- Strata Skin Sciences reports Q4 EPS ($1.18), consensus (40c)
- SSKN Earnings Report this Week: Is It a Buy, Ahead of Earnings?